KOPRAN. share price has zoomed 6% and is presently trading at Rs 266.4.
Meanwhile, the BSE HEALTHCARE index is at 38,114.1 (down 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are MAX HEALTHCARE INSTITUTE (up 2.0%) and GLAND PHARMA (up 1.9%).
Divis Laboratories (down 3.1%) and CAPLIN POINT (down 2.7%) are among the top losers today.
Over the last one year, KOPRAN. has moved up from Rs 187.6 to Rs 266.4, registering a gain of Rs 78.8 (up 42.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,703.5 to 38,114.1, registering a gain of 48.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 107.6%), Cadila Healthcare (up 104.1%) and Lupin (up 99.0%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,897.2 (down 0.1%).
The top losers among the BSE Sensex today are Titan (down 4.0%) and MUNDRA PORT & SEZ (down 2.0%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.
In the meantime, NSE Nifty is at 24,272.7 (down 0.2%). Titan and Divis Laboratories are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,479.1 to 79,897.2, registering a gain of 14,418.2 points (up 22.0%).
KOPRAN. net profit grew 131.6% YoY to Rs 186 million for the quarter ended March 2024, compared to a profit of Rs 80 million a year ago. Net sales rose 25.0% to Rs 1,861 million during the period as against Rs 1,489 million in January-March 2023.
For the year ended March 2023, KOPRAN. reported 55.4% decrease in net profit to Rs 272 million compared to net profit of Rs 610 million during FY22. Revenue of the company grew 15.4% to Rs 5,510 million during FY23.
The current Price to earnings ratio of KOPRAN., based on rolling 12 month earnings, stands at 25.2.
Equitymaster requests your view! Post a comment on "KOPRAN. Gains 6%; BSE HEALTHCARE Index Down 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!